Adaptive Biotechnologies insider plans $7.5M sale

For ticker ADPT, Harlan Robins filed a notice of intent to sell 300,992 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $7,455,571.84, in transactions expected on or after 08/17/2026.

Rhea-AI Filing Summary

For ticker ADPT, Harlan Robins filed a notice of intent to sell 300,992 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $7,455,571.84, in transactions expected on or after 08/17/2026.

The shares to be sold include stock acquired as performance awards on 03/10/2026 and through stock options granted 02/07/2019, including a cashless exercise/same‑day sale component. The filing also lists multiple prior common stock sales by Robins during June and July 2026.

Key Figures

Shares proposed to be sold: 300,992 shares Aggregate market value of proposed sale: $7,455,571.84 Proposed sale date: 08/17/2026 +5 more

8 metrics

Shares proposed to be sold 300,992 shares Common stock covered by the notice of proposed sale

Aggregate market value of proposed sale $7,455,571.84 Market value of 300,992 shares of common stock

Proposed sale date 08/17/2026 Expected start date for sales of covered shares

Sale 1 shares and value 207,600 shares; $4,538,136 Common stock sale on 07/21/2026

Sale 2 shares and value 284,800 shares; $6,225,728 Common stock sale on 07/21/2026

Sale 3 shares and value 100,000 shares; $1,737,460 Common stock sale on 06/15/2026

Sale 4 shares and value 6,160 shares; $110,945.91 Common stock sale on 06/16/2026

Sale 5 shares and value 250,000 shares; $5,565,550 Common stock sale on 07/02/2026

Key Terms

Form 144, cashless exercise / same-day sale, Performance Awards, compensation -- Stock Options, +1 more

5 terms

Form 144 regulatory

"144: Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

cashless exercise / same-day sale financial

"148956 | 02/07/2019 | Compensation -- Cashless exercise / same-day sale"

Performance Awards financial

"03/10/2026 | Acquired as compensation -- Performance Awards"

compensation -- Stock Options financial

"02/07/2019 | Acquired as compensation -- Stock Options"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ADPT by Harlan Robins disclose?

The filing discloses an intent to sell 300,992 shares of ADPT common stock, with an aggregate market value of $7,455,571.84, to be executed through Goldman Sachs & Co. LLC on or after 08/17/2026.

How many ADPT shares is Harlan Robins planning to sell under this Form 144?

Harlan Robins plans to sell 300,992 shares of ADPT common stock. The filing lists these shares with an aggregate market value of $7,455,571.84 in connection with proposed sales beginning on or after 08/17/2026.

What is the aggregate market value of the ADPT shares covered by this Form 144?

The aggregate market value of the ADPT shares covered is $7,455,571.84. This value relates to the planned sale of 300,992 shares of common stock through Goldman Sachs & Co. LLC as disclosed in the notice.

When are the proposed sales of ADPT stock by Harlan Robins expected to occur?

The proposed sales are expected on or after 08/17/2026. This date is listed as the proposed sale date for the 300,992 shares of ADPT common stock covered by the Form 144 filing.

What prior ADPT stock sales by Harlan Robins are reported in the last 3 months?

Reported sales include 207,600 shares and 284,800 shares on 07/21/2026, 136,240 shares and 250,000 shares on 07/02/2026, and 100,000 shares and 6,160 shares on 06/15–16/2026, all common stock.

How were the ADPT shares to be sold by Harlan Robins originally acquired?

The shares were acquired as compensation, including performance awards dated 03/10/2026 and stock options dated 02/07/2019. Part of the planned transactions involves a cashless exercise / same-day sale of option shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 05:21 PM Accepted by SEC EDGAR 08/17/2026 - 05:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001780851
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Adaptive Biotechnologies Corporation
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	1-206-659-0067
Name of Person for Whose Account the Securities are To Be Sold	Harlan Robins
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	300992	7455571.84	159595842	08/17/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/10/2026	Acquired as compensation -- Performance Awards	The Issuer			152036	03/10/2026	Compensation
Common Stock	02/07/2019	Acquired as compensation -- Stock Options	The Issuer			148956	02/07/2019	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/21/2026	207600	4538136
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/21/2026	284800	6225728
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	06/15/2026	100000	1737460
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	06/16/2026	6160	110945.91
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/02/2026	136240	2936094.62
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/02/2026	250000	5565550

144: Remarks and Signature

Remarks
Date of Notice	08/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Harlan Robins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)